Skip to content

Clinical trials

Observational Myeloproliferative Disorders trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myeloproliferative Disorders Phase: Observational Country / region: United States Clear all

47 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20065
20077
20087
20095
20102
20141
20151
20162
20181
20193
20202
20211
20221
20231
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed26
Terminated10
Recruiting8
Active, not recruiting1
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
City of Hope Medical Center4
Vanderbilt-Ingram Cancer Center4
OHSU Knight Cancer Institute3
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS2
Icahn School of Medicine at Mount Sinai2
Incyte Corporation2
Mayo Clinic2
SWOG Cancer Research Network2
UNC Lineberger Comprehensive Cancer Center2
University of Utah2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myeloproliferative Disorders47
Primary Myelofibrosis24
Myelodysplastic Syndromes23
Leukemia, Myeloid, Acute22
Multiple Myeloma22
Lymphoma, Non-Hodgkin21
Precursor Cell Lymphoblastic Leukemia-Lymphoma21
Hodgkin Disease20
Leukemia, Lymphocytic, Chronic, B-Cell20
Blast Crisis19

Trials

Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.